Name (Synonyms) | Correlation | |
---|---|---|
drug2174 | Placebo: Emtricitabine/tenofovir disoproxil Placebo Wiki | 1.00 |
drug2175 | Placebo: Hydroxychloroquine Wiki | 1.00 |
drug996 | Emtricitabine/tenofovir disoproxil Wiki | 1.00 |
drug1284 | Hydroxychloroquine Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The primary objective of the study is to evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU. The primary endpoint is the occurrence of a major event predefined as either: death (all-cause mortality) or discharge from ICU (limit of 4 months). This is a uni-center prospective observational cohort study with an inclusion period of 2 months. The end of the study is foreseen in 6 months.
Description: Covid-19 pneumonia that requires ICU admission can go either way.
Measure: Death (all-cause mortality) or discharge from ICU (limit of 4 months) Time: 4 months